Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

1. PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Brazil Drug Forecast
and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative
bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective
diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by
vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account
for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData
expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B
vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants
and/or provide a longer duration of immunity also have an opportunity to seize market share during
2012-2022.
GlobalData predicts that market share for private vaccine manufacturers to virtually disappear over the course
of the forecast, with Brazil unleashing domestically-produced MenC conjugate vaccines that are more
cost-effective for the government-funded healthcare system. These vaccines, which include a MenC conjugate
vaccine and a heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and produced
by government-sponsored institutions such as Bio-Manguinhos, Instituto Butantan, Fiocruz, and FUNED.
Once they become widely available, these vaccines will quickly steal market share from private manufacturers
because of their cost-effectiveness advantage.
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key
drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis. Sales
forecast for the top drugs in Brazil from 2012-2022. Analysis of the impact of key events as well the drivers
and restraints affecting Brazil Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of
the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively
plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make
more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales
forecast for drugs from 2012-2022 in Brazil
table Of Contents
1 Table Of Contents 4
1.1 List Of Tables 7
1.2 List Of Figures 9
PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

2. 2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology And Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 17
3.2 Symptoms 19
3.3 Prognosis 20
4 Disease Management 21
4.1 Meningococcal Immunization Policy 22
4.2 Brazil 24
4.2.1 Meningococcal Immunization Recommendations And Policies 24
4.2.2 Clinical Practice 26
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 28
5.3 Product Profiles Major Brands 30
5.3.1 Meningitec 30
5.3.2 Menjugate 33
5.3.3 Neisvac-c 36
6 Opportunity And Unmet Need 39
6.1 Overview 39
6.2 Unmet Needs 40
6.2.1 Unmet Need: Protection Against Serogroup B Disease 40
6.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 41
6.2.3 Unmet Need: More Cost-effective Vaccines 42
6.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 43
6.2.5 Unmet Need: Immunogenic Infant Vaccines 45
6.2.6 Unmet Need: Improved Vaccination Coverage Rates 46
6.2.7 Unmet Need: Increased Patient Awareness And Education 47
6.3 Unmet Needs Gap Analysis 48
6.4 Opportunities 49
6.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 49
PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

3. 6.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 50
6.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
Markets 51
7 Pipeline Assessment 52
7.1 Overview 52
7.2 Promising Vaccines In Clinical Development 53
7.2.1 Promising Vaccines In Early Clinical Development 56
7.2.2 Meninge Acyw Conj. 57
7.2.3 Menabcwy 61
7.2.4 Menc Conjugate 64
7.2.5 Heptavalent Dtp-hib-hepb-ipv-menc 67
8 Market Outlook 70
8.1 Brazil 70
8.1.1 Forecast 70
8.1.2 Key Events 73
8.1.3 Drivers And Barriers 74
9 Appendix 76
9.1 Bibliography 76
9.2 Abbreviations 87
9.3 Methodology 90
9.4 Forecasting Methodology 90
9.4.1 Vaccine Coverage 91
9.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 91
9.4.3 Vaccines Included 92
9.4.4 General Pricing Assumptions 93
9.4.5 Individual Vaccine Assumptions 94
9.5 Physicians And Specialists Included In This Study 97
9.6 About The Authors 101
9.6.1 Authors 101
9.6.2 Reviewers 101
9.6.3 Global Head Of Healthcare 103
9.7 About Globaldata 104
9.8 Disclaimer 104
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

4. industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022